JAPANESE MEDICAL MATERIAL

1. 242

THYMOPHOGEN

(Sodium 4-chlorthymol-phosphate)

291782

Medical No. 230

APMY MEDICAL SEF 23 1946 LIBRARY

24 May 1946

MEDICAL ANALYSIS SECTION 5250 Technical Intelligence Company APC 500

THYMOPHOGEN


(Sodium 4-chlorthymol-phosphate)

SOURCE: Tokyo, Japan.

IMPORTANCE: Not previously reported. An organic compound for which bactericidal action against the tubercle bacilli is claimed. No identical product is listed in available American references.

DESCRIPTION: Six amber tinted ampuls, each containing 1.0 gm. of a white powder, are enclosed in a cardboard box.

SUMMARY OF GENERAL INFORMATION: Thymophogen is sodium mono 4chlorthymol phosphate:



Thymophogen in itself is not bactericidal but is claimed to be decomposed in the body by phosphatase and the high hydrogen for concentration of the infected area to liberate 4-chloro-thymol. This compound has the proerty of penetrating the Lipoids which are in the tissues near the infection, thereby reaching the foci where its anti-tubercular action occurs.

It is available in the following forms and sizes:

Ampuls: 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.5, and 2.0 gm.

Each is furnished in containers of either 6 or 36 ampuls.

Vials: 2.0, 5.0, and 25 gm.

The ampuls are intended for sterile injectable solutions in a 4 to 5% concentration in distilled water or glucose (5 - 10%). Parenteral dosage begins with 0.2 gm., administered daily or on alternate days, and is gradually increased to approximately 1.0 gm. A dosage table is included for use as a guide. The blood vessels receiving the injections of thymophogen become hardened if leakage occurs and in such cases a period of rest is prescribed to allow the blood vessels to renew their elasticity.

The powder (0.1 to 02%) is to be dissolved in physiological salt solution (1.0 to 1.5%) and vaporized for inhalation. No restriction is placed on the inhalation method of treatment.

A translation of the literature enclosed with the product is part of this report and includes its chemistry, pharmacology, indications, routes of administration, dosage, cautions, toxicology, packaging and manufacturer.


PHOTOGRAPHS:

Figure 1 - Closed package of Thymophogen

Figure 2 - Open package of Thymophogen

Figure 3 - Thymophogen literature





結核化學療法特別衝樂

特許。チモフオーゲン 移譲注射用

THYMOPHOGEN

「チモフオーゲン」の準成及び性狀

結정面に對する疫動作用「四・クロールチモール」の性状と

患の化學療法の理論竝に體内製化『チモフオーゲン』による結核性疾

するものに手す。 改したるエステル難にして、此のエステル強なる非銀にては指し我指力を行 本柄は歩名の示す如く「困・クロールチャール」と特徴との結合によるて改

「チモフオーゲン」の信内變化 CH: CH: CH CH H-C C-O-P-O +H₂ O- H-C C-OH+PO4IN₈₂
CI-C C-H ONa CI-C C-H CH.
Themphages
(Man-4-blat thymyl-phosphoromics Natrum) 4-blat thymyl-phosphoromics Natrum, 4-blat thymol
高・ニケドキラシュラスを選びるロンサポモラのの(対話を記)
は世紀では立ち下れらなって、歴史改革が125年 17年まりの(対話を置)

「チモフオーゲン」の忍客性と副作用

「本年です」と、「の節音な知り、 は、第一を発展という。「の節音な知り、 同一かかかのの場合にあっている。 なの命のの場合にあっている。 では、「「「「「「」」」」 では、「「「「「」」」」 では、「「「「」」」」 では、「「」」」」 では、「「」」」 では、「」」」 では、「」」」 では、「」」」 では、「」」」 では、「」」」 では、「」」」 では、「」」」 では、「」」」 では、「」」」 できた。「」」 できた。「」」 できた。「」」 できた。「」」 できた。「」 できた。「 できた。 できたた。 できた。 できた。 できた。 できたた。 できたた。 できたた。 できた。 できたた。 できたたまたた。 できたたまたた。 できたた。 できたた。 できたた。 できたた。 できたたまたた。 できたたまた。 できたたまた。 できたた。 できたた。 できたた。 できたた。 できたたた。 できたたた。 できたたた。 できたたた。 できたたた。 できたたた。 できたたで、 できたたで できたたたで できたたたで できたたで できたたで できたたたで できたたたたで できたたたで できたたた

「チモフオーゲン」の警治效用

「チモフオーゲン」の通感症

8条、カリエス、可護監督・動動物・結構性の音楽・結構性態を、生物な動物・生物な動物・耐性・耐性・耐性・動物を、 1 中間浸潤・結構性的現実・結構性

節故・古術語故・職以以及の治治問題・其他語言其法院與以正述學故而明不養 **寛により後防内質値つ部性とうと趣思さる。 台籍地質値に終て詳細なな事するも本性はははは、り間を発送せ上ひるの事態と外目として明直はは、な解説は、子宮町紙・青紅斑雀・香蕉等に乗用す。衛父外目として明白は、フロキの書・手側編件は調果出級に条件に応される。**

「チモフオーゲン」特級内注射の用量 拉に注意

と、治療直後展別の治失するよ見定め法理して診臓内法科を行ふ(サルスル・、治療直後知治の治失す(よりスル、質の治二の治疗を二氏症の法証本(五々文は一〇年の治療療食も可)に溶解性強性疾病性疾性病は治生を治氏はよます。 即ち嫌品

治療領域及其の用法用意『チモフオーゲン』の外用拉に吸入用としての

外科的織用の用法用単は大略左記の加くなると問題状策各使の政策を乞ふ

資金のよいが、○・1名、刺媒ルなき場合は新州上で「•○会以上に東る各族的水に別る(?1名、刺媒化なさず、古物子無用す、面上で非額度は集異的条件、副中では調整のは新性残争の計解性残象に対し其様数により固むます。

し、日二回行名を開発を示していませた。 「新知し」「ついま」とは記念であるのにして、我の「国用意は五〇四円外と今に振行さら、明立は他的自動の表現となる。「古文は〇二 [224-5]が、「東入日後 高利泉大村として明明され、新昭村、東西で、東京大橋路線とは、「大丁。

ale		2,50	3,20	28,000	30,50	96,00	7,80	10,20	12,30	2		2,00	250	8
#	厩	dip.	app.	orp.	44	mp.	da da	44		中部		64	cy.	50
教食林	=	0,16. (SAmp.	O.2G. SAMP.	OAG SKAPP.	0,8G, SAmp.	O.S.G. S.	LOCK, SAMP.	150. SAMP.	Yr.B 2,0G, SAmp.	(減量処理水道粉セス)	最大並に外用	製み	3	1
据	_	2	20.	10.	D.	9	XA.	0	G.	開発開	X		46	4
-80	*								2,0	報告		2,06	5,00	DE OF
		Nr.	Nr.2	Sr.3	Nr.6	Sr.5	Str.6	248	S'T'S	9		CN.	22	ANE

部原用へ調査をよる毎回報告ナル連門以降と行と数品・現化と関さるこ 「チモフオーゲン」用意表

- A		=; *		14	7																												
中る場合	0.2gr	0,2gr	0,2gr	0.2gr	0.4gr.>	STAIL OPER	発量すりらず	0.4gr	10,4gr	0.4gr	O.Age	18970	14 th 10 0.4gr	馬服中司名す	0.6gr	0,687	0.587	0,5947	0.8gr			0.8gr	O.High	0.9gr	0.8gr	1.0gr	中地震 0.8四年 東海大田の子			1,087	3,0 gce	180'I	ar 液種の塩
遊遊	16.28	18 3E	图6 班	SF 513	150 GE	16. 1. 经股份	學使用几	部 7田	100 8 10		\$8101	1811E		出	##12E	\$136			\$51618	29	學學	1817 E	BIBE	ELG13	(\$20H	第21日	もし強然を使用し	\$\$22.E	\$\$23E	\$\$24.H	#K5511	HE CO EL	14.85 7.0
10	O.Agr	0.4gr	0.4gr	O.4gr	O.6gr		1年18日十	0,687	O.6gr	D.Ggr	0,0gr	0,8gr			0,8gr	O.Pgr	0.880	0.887	170gr	æ.	(iii		1000	1837	1.0gr	1,0gr	単版の本						
安裝	CV		4	10	10	-2	56.3	3	8	Oil	1810H	1811日	毛上四路少松	全使用し帮品	第12日	181311	Heist	9875 EB	\$518 EE		全被加上都是	B2188					以表 1.0四型						
	総会公の場合 教験中の場合	監査を3る場合 教験せる場合 2日 0.4gr 年2日 0.2gr	総合 2 2 場合	高を言る場合 数数を 5 場合 2gr 5 2H 0.2gr 6 2H 0.2gr 4 3H 0.2gr 4 4H 0.2gr 6 4H 0.2gr	(株式 2 3 場合	88 までる場合		 24 日本書の場合 25 日本書の場合 26 日本書の場合 27 日本書の名 27	製造を変え場合			10 10 10 10 10 10 10 10	10 10 10 10 10 10 10 10	第2 年 2	10 10 10 10 10 10 10 10	Section Sect	10 10 10 10 10 10 10 10	100 100	## 2	1	100 100	10 10 10 10 10 10 10 10	10 10 10 10 10 10 10 10	100 100	100 100	100 100	10 10 10 10 10 10 10 10	10 10 10 10 10 10 10 10	100 100	100 100	10 10 10 10 10 10 10 10	100 100	10 10 10 10 10 10 10 10

別位置所立 三星藥品株式會社 礼館市外學は一〇九 幸遠 強攻 島 题 權 機 一字明章元 "東京市中央資源水町三丁十二

TRANSLATION OF LITERATURE ACCOMPANYING THYMOPHOGEN

THYMOPHOGEN

Mono 4-chlorthymol-phosphorsaures natrium A specific Tuberculosis chemotherapeutic.

For intravenous injection, inhalation and external use. Experimented and recommended by Dr. Eiji Arima, Professor in the Medical Department of the Hokkaido Imperial University.

Discovered by Dr. Takeichiro Ayukawa, Assistant professor in the Medical Department of the Hokkaido Imperial University.

THYMOPHOGEN is the product of the untiring effort of Dr. Ayukawa, who intended to cure tuberculosis for more than ten years. At the beginning of the study many tubercle bacilli bactericides were found. Among them 4-chlorthymol, a specific, not affected by the existence of albumen, was discovered. It can be used in living bodies. It resembles salvarsan and other arsenicals that can be used in living bodies although arsenic itself can not be used directly.

The chemical and bacteriological studies were carried on at the medical chemistry and the dermatology sections respectively. One part of the report was already published in 1930. Due to ceaseless effort and studies, it has attained perfection as an anti-tuberculosis specific. Since 1934, Dr. Arima, professor of the 1st. internal department of the Hokkaido Imperial University, has performed many experiments

on both the bacillus and with animals.

These excellent results were reported to the people at the 14th General Meeting of the Japanese Tuberculosis Association by a special speech given by the men on this research, Dr. Arima and Dr. Sasaki, one of the assistants at Arima's Internal Laboratory. The experiments were done at the pharmacological sections of surgery, gynaecology, and pediatry. (Published by Dr. Yoshida at the 34th Japan Gynaecology Association).

The results of supplementary experiments were published at the 15th General Meeting of the Japanese Tuberculosis

Association by doctors and clinical doctors.

On November 11, 1937, at the autumn Extraordinary Meeting of the Hokkaido Medical Society, the following reports were published: "The Application of Medicine to Renal Tuberculosis" by Dr. Ryo Shiga, professor at the skin and urinary section of the Hokkaîdo Imperial University, "The Application of Under Mucous Membrane Injection for Tuberculosis of Fauces", by Bachelor Tsunehisa Yanai, professor at the otorhinolaryngology section, and "The Inhalation Treatment for Tuberculosis of Fauces", by Bachelors Nobuyuki Ozawa, Kakugoro Kondo and Kinji Kachi of the 1st internal section.

From April, 1-4, 1938, at the 16th Japan Tuberculosis Meeting held in Kyoto, several lectures and influential supplementary lectures were given.

In October, 1938, at the local meeting of Dai-Nippon Dermatology and Ureology Association in Osaka, the clinical results of this medicine against renal tuberculosis were presented by Dr. Nishimura and five other doctors of the

medical department of the Osaka Imperial University.

In October, 1938, at the local meeting of Dai-Nippon
Otorhinolaryngology Association, in Osaka, Dr. Furukawa
of the Wakayama Public Hospital lectured on the reaction of

the medicine toward tuberculosis of the fauces.

Following this, the gist of the action of this medicine was reported in the Japanese clinical medicine magazine "Clinical Medicine of Japan" issue of November, 1938.

In the December, 1938 issue of "Treatment and Prescript-

ions". Dr. Inui of the Miyagi-branch of the Japanese Red Cross, showed an example of this medicine applied to both tuberculosis of fauces and pulmonary phthisis.
In the January, 1939 issue of "Japanese New Treatments",

a treatise connected with this remedy was published.

In the February, 1939 issue of the "Medical Experiments", we saw the treatise, "Experience in the use of Thymophogen to Surgical Tuberculosis, such as Caries, and Articular Tuberculosis".

In "Tuberculosis" vol. 17, No. 1, Bachelor Kinji Kazi, student at the 1st internal section of the graduate school of the Hokkaido Imperial University, published a treatise entitled "The Study of the Action of Thymophogen Preventing the Growth of the Bacteria of Tuberculosis".

All these facts have pronounced the accurate effect of this remedy, and it's practical effects have been proven

widely.

COMPOSITION AND CHARACTER OF THYMOPHOGEN

This is a chemical compound with the following formula: * (CH₃)₂CH.C₃E₂C1.CH₃.O PO₃Ne₂ (Mono 4-chlorthymol-phosphor-saures natrium). It is a colorless, oderless, pin-like crystal with silky lustre. The actual drug appears as a white powder, easily soluble in water. Its water solution is weakly alkaline. It resists alkali but is easily hydrolyzed by acids or phosphatase of the body to 4-chlorthymol (CH3) 2CH.C6H2.Cl.CH3.OH (cf. respective books).

NATURE AND ANTI*TUBERCULOSIS BACILLUS ACTION OF 4-CHLORTHYMOL

This is one phenol with a pleasant odor. The colorless crystal plates are insoluble in water, soluble in caustic alkali liquids, easily soluble in organic solvents, and it's solution has the special character of being lipoid soluble.

Its bactericidal action against the tuberculosis bacillus is so vigorous that it destroys the bacillus in concentrations of 1/100,000 - 1/1,000,000. If a 0.02% solution is used, it

acts in less than one hour.

*(T.N. This is probably an error and should be corrected to read (CH3) 2 CH C6H2 C1 CH3 O PO3Na2)

The principal reasons are:

(a) As it is lipoid soluble, it easily penetrates through the lipoid membrane of the tuberculosis bacillus.

This can not be done by other bactericides.

(b) It is not affected by the existence of albumen. It is clear, from reference sources, that both Guaiacol and Carvacrol, an isomer of thymol, haven't bactericidal action against tuberculosis bacillus.

THORY OF THYMOPHOGEN AND ITS PHYSIOLOGY

As the chemical name shows, it is an ester salt produced by reacting 4-chlorthymol with phosphoric acid, but

in this state it has no bactericidal power at all.

When it is ingested into the living body it is hydrolyzed by phosphatase and by the high hydrogen ion concentration of the infected area. Then the 4-chlorthymol penetrates the lipoid which is in the tissue near the tubercular infections, and reaches the foci where it acts as a powerful bactericide.

The fact that the Thymophogen is easily decomposed in the infected part is well proven by the peculiar effects resembling fever which develope when an injection is made. This is why it is claimed by clinical doctors to be a diag-

nostic for infected areas.

Thymophogen
(Mono 4-chlorthymolphosphorsaures natrium)

4-chlorthymol

TRANSFORMATION OF THYMOPHOGEN IN THE BODY

The 4-chlorthymol which was formed by the hydrolysis of Thymophogen is excreted as conjugations of glucuronic and sulfuric acids.

ADMISSIBILITY AND SECONDARY REACTION OF THYMOPHOGEN

The composition as I wrote above is quite poisonless to the living body. At an experiment, we could not observe any secondary reaction after injecting intravenously 10 cc of a 20% solution (equal to 2.0 Gm. of powder) into a rabbit weighing 1.6 Kg. Judging from this it can be given to men without danger.

However, when one has many focal infections it is decomposed rapidly according to the reason above, so I warn you on its dosage when it is used in clinics. The maximum dosage for humans was found to be 2.0 Gm. of powder daily. If the amount is increased gradually, secondary reactions will not occur. There is no danger if a small quantity escapes from the vein.

We had better not use it when there are fractures of bones, because a remarkable reaction would occur in the living body owing to the sudden decomposition by phosphatase.

THE MEDICAL USE OF THYMOPHOGEN

You can expect the following effect in anti-tuberculosis treatment:

1. Recovery of the precipitation speed of red blood-corpuscles.

2. Speedy coagulation of blood.

3. Decreased tuberculosis bacillus in the sputum.

4. The febrifuge action.

5. The sedative and hypnotic action.6. Increase of appetite.

6. Increase of appetite7. Increase of weight.8. Antitussive action.

9. Decrease of phlegm.

INDICATIONS

Pulmonary phthisis, tuberculosis of pulmonary lymph nodes, catarrh of the pulmonary apex, early infiltration, tubercular pleurisy, tubercular peritonitis, caries, tuberculosis of the kidney, glandular tuberculosis, nodular tuberculosis, tuberculosis of the bronchial tract, tuberculosis of sexual organs, skin tuberculosis, scrofula, asthma of the bronchi, tuberculosis of pharynx, uterine tuberculosis, tuberculosis of b one, anal fistula, and other tubercular conditions.

We can estimate it's value as a preventive by the fact that it destroys the bacilli that are injected into the test

animals.

DOSAGES AND CAUTION IN THE INTRAVENOUS USE OF THYMOPHOGEN

Density: The suitable density is 4% to 5% in sterilized water or in a 5% to 10% solution of glucose. Allow the bubbles to break, and inject slowly and carefully into the vein.

Dosage: (Relation between reaction and dose) For Adult: Begin with 0.2 Gm., to 0.4 Gm. (0.2 Gm. for females or serious cases) and watch for reactions. (In chronic cases we can hardly see any reaction with 0.2 Gm. to 0.4 Gm.). When large doses, such as 0.4 Gm., 0.6 Gm., 0.8 Gm., and 1.0 Gm. are reached, repeat the doses several times. The injections are to be given daily or on alternate days.

In case of internal infection such as pulmonary tuberculosis, continue the injection keeping the maximum dose at
1.0 Gm. but in case of external disease, such as caries, use
1.5 Gm. to 2.0 Gm. each time, though at times more than 2.0
Gm. may be used. However, you must remember that when it escapes from the blood vessel, the local area where it escaped
becomes calloused. If leakage occurs, stop the injection.
One series consists of 25 Gm. to 40 Gm. Allow the blood vessel
to recover for a period of 10 to 30 days. Generally one series
will satisfactorily improve the disease.

Occasionally, in case of severe weakness or when the reaction continues it is better to divide the series into several terms and have rest periods of 5 to 7 days. This method

is also used when the disease is severe or chronic.

The maximum dosage: For internal use ordinarily 1.0 Gm., in very rare instances 1.5 Gm. For external use: 2.0 Gm. The required dose varies in each instance.

Reaction of injection: This is not a secondary reaction but an inevitable pharmacological reaction due to the destruction of the tuberculosis bacillus by 4-chlorthymol

which was formed in the diseased part.

The outlook of the reaction: In 35 to 60 seconds after the injection the patient feels a tingling sensation, generally proportionate to the degree of the illness. In an infection in the lungs, the patient may be affected by irritation of the breast and light dyspnea, and occasionally by a headache. This will disappear in 5 to 10 minutes. Ordinarily the patient will sleep comfortably for 1 to 5 hours after the injection. Sometimes the whole body feels tired and a slight ache is present in the diseased area, but all these reactions disappear in a short while. Very rarely one is affected by a fever of 38° to 39°C for about 30 minutes after the injection. Ordinarily the temperature returns to normal in 3 to 5 hours. Rarely the patient is affected by a temporary decrease of appetite or a decrease of weight. We could not recognize any dangerous reactions during the injection of the large amount of the remedy. All these reactions decrease with each injection, until no reactions are observed. The patient will then begin to gain weight.

The relation between reactions and the increase of dose:
Naturally the reaction depends on the constitution, the size
of the infection, and the amount of the injection. Nevertheless, if a large amount (0.8 Gm. to 1.0 Gm.) is injected,
it will produce a chill or fever without fail. To avoid these
strong reactions, the injection should be started in small
amounts, 0.2 Gm. for serious victims and 0.4 Gm. for general
patients, increasing the amount slowly. Ordinarily we can
observe some reactions in the first increased injection, but
that will disappear as repeated injections of the same dosages
are given. When the dose of 0.6 Gm. is reached, repeat the
injection several times even if you can not recognize any reactions. If you increase the dosage suddenly when the dose of
0.6 Gm. or 0.8 Gm. is reached, severe reaction will appear.

If you observe a strong reaction, regardless of the amount you have been giving, diminish the amount of the injection and wait for the opportunity to increase it again.

The dosage after a rest: After 5 days of rest following a series, the first injection must be commenced from 1 or 2 units lower than the highest amount previously given. For example, give 0.6 Gm. if a 1.0 Gm. injection had been used before the rest. Of course, note must be taken on the reaction in the case of the injections after the rest, but the dosage will be increased comparatively rapidly to the highest amount before the rest.

Caution: This medicine must not be used together with intravenous injections of calcium preparations for at least 24 hours. Nevertheless, calcium preparations may be used externally or orally. No dangerous reactions have been noted

in other oral medications.

Thymophogen for external and inhalation use, method of treatment, and dosage by these routes: Experience has proved the following, but treatment must be at the discretion of the doctor.

(a) For tubercular diseases of the bone-marrow, joints, anus, skin, lymphatic glands, etc., wash, or use gauze compresses, wetted in 0.2 to 1.0 % solution in physiological salt solution. A stronger solution may be used if reaction does not occur.

(b) For tuberculosis of the skin, use a 0.4 to 1.0 %

ointment.

(c) For tuberculosis of fauces begin with 0.3 % and increase the strenght gradually. There are examples where a 10 % solution has been used. Inject 1 to 2 cc in small quantities subcutaneously in the infected area (use a special made large needle). Compresses with a small quantity of a local anesthetic are advantageous.

(d) Dosage for inhalation use: Applied for tuberculosis of fauces, pulmonary tuberculosis, lung gangrene, bronchial dilation, etc., by inhalation of steam. Dissolve 0.1 % to 0.2 % of this in 1.0 % to 1.5 % of physiological salt sol-

ution. Use about 50 cc per dose, twice a day.

Package and price for intravenous use.

#1	0.1 Gm.	6 Amp.	¥ 2.50 12.50	
#2	0.2 Gm.	6 "	3.20	
#3	0.4 Gm.	6 "	4.50	
#4	0.6 Gm.	6 "	24.00	
#5	0.8 Gm.	6 "	30.50	(sterilized,
#6	1.0 Gm.	6 "	36.00 7.80	distilled water is not supplied)
#7	1.5 Gm.	36 "	42.00	
#8	2.0 Gm.	36 "	55.00 12.00 66.00	

For inhalation and external use

2.0	Gm.	Vial	¥	2.00
5.0	Gm.	Vial	¥	4.50
25.0	Gm.	Vial	Y	6.00

Note: Each lot is sterilized and biologically tested to insure purity.

Table of dose of THYMOPHOGEN

This table is the standard dose. Individual doses must be computed by reaction, fever, severity of the disease and

the prognosis.

The opinion of many doctors is that the maximum dose to be given is 0.6 Gm. for women and children, and 0.8 Gm. for men, and that this should be the maintenance dose until the cure is effected.

For external use, 2.0 Gm. should be considered the max-

imum dose.

ADULT DOSE TABLE

The 1st day 0.4 Gm. (0.2 Gm. for female or serious victims)

	Fever	present		Fever	abse	nt
3rd 4th 5th	day day day day	O.2 Gm. O.2 Gm. O.2 Gm. O.2 Gm. O.4 Gm.	3rd 4th 5th	day day day day	0.4	Gm. Gm.

If the patient has fever use 0.2 Gm. and do not increase the amount.

7th	day	0.4	Gm.	
8th	day	0.4	Gm.	
9th	day	0.4	Gm.	
10th	day	0.4	Gm.	
11th	day	0.6	Gm.	

If the patient has fever use 0.4 Gm. and do not increase the amount.

12th	day	0.6	Gm.
13th	day	0.6	Gm.
14th	day	0.6	Gm.
15th	day	0.6	Gm.
16th	day	0.8	Gm.

If the patient has fever use 0.6 Gm. and do not increase the amount.

17th	day	0.8	Gm.
18th	day	0.8	Gm.
19th	day	0.8	Gm.
20th	day	0.8	Gm.
21st	day	1.0	Gm.

If the patient has fever use 0.8 Gm. and do not increase the amount.

22nd	day	1.0	Gm.
23rd	day	1.0	Gm.
24th	day	1.0	Gm.
25th	day	1.0	Gm.
26th	day	1.0	Gm.

If the patient has fever use 0.4 Gm. and do not increase the amount.

7th	day	0.6	Gm.
8th	day	0.6	Gm.
9th	day	0.6	Gm.
10th	day	0.6	Gm.
llth	day	0.8	Gm.

If the patient has fever use 0.6 Gm. and do not increase the amount.

12th	day	0.8	Gm.
13th	day	0.8	Gm.
14th	day	0.8	Gm.
15th	day	0.8	Gm.
16th	day	1.0	Gm.

If the patient has fever use 0.8 Gm. and do not increase the amount.

17th	day	1.0	Gm.
18th		1.0	GIII.
19th	day	1.0	Gm.
20th		1.0	
21th	day	1.0	Gm.

Manufactured and distributed by Mitsuboshi-Seiyaku Co., Ltd., 109, Kinji, Suburb of Sapporo City. Sole Agency: Torii Co., Ltd., Honcho 3-chome, Nihonbashi-Ku, Tokyo.